Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.43 (4.43%)
Data as of 11/14/18 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
11/09/18Eiger Bio Reports Third Quarter 2018 Financial Results
10/23/18Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
10/22/18Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
10/22/18Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
Upcoming EventsMore >>
Eiger BioPharmaceuticals at the Obesity Week
Eiger BioPharmaceuticals at the Piper Jaffray Healthcare Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.